This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Enzo Life Sciences
other brands :
Stressgen, BioMol, Alexis Corporation, Assay Designs, Alexis
product type :
chemical
product name :
Embelin
catalog :
BML-CM125-0050
quantity :
50 mg
citations: 1
Reference |
---|
Nikolovska Coleska Z, Xu L, Hu Z, Tomita Y, Li P, Roller P, et al. Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database. J Med Chem. 2004;47:2430-40 pubmed
|
product information
Product ID :
BML-CM125
Catalog Number :
BML-CM125-0050
Product Name :
Embelin
Product Type :
Biochemical
Size :
50 mg
list of Pubmed id :
15115387
Product Description :
Embelin is a novel cell-permeable inhibitor of XIAP (X-linked inhibitor of apoptosis) which was discovered by screening a library of natural products derived from traditional Chinese medicine. It binds to the XIAP BIR3 domain preventing its binding to and inhibition of caspase-9 and effector caspases. Embelin selectively inhibits cell growth in cancer cells expressing high levels of XIAP (IC50 = 3-6 µM) versus normal cells with low levels of XIAP.
ALTnames :
Embelic acid
Purity :
≥98% (HPLC)
Storage :
-20°C
company information
Enzo Life Sciences
5777 Hines Drive
Ann Arbor, MI 48108
Ann Arbor, MI 48108
info-us@enzolifesciences.
https://www.enzolifesciences.com1-800-942-0430
headquarters: USA
Enzo Life Sciences, incorporating ALEXIS® Biochemicals and BIOMOL® International, offers a comprehensive panel of innovative life science reagents. Antibodies, enzymes, proteins, small molecule inhibitors, product libraries, and assay kits are available for research in Cancer, Cell Death, Epigenetics, Genomics, Immunology, Neuroscience, Signal Transduction, and Ubiquitin & Proteasomes, Enabling Discovery in Life Science(tm). Visit www.enzolifesciences.com.
questions and comments